David A. Siegel Olema Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Olema Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 144,400 shares of OLMA stock, worth $1.45 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
144,400
Previous 138,000
4.64%
Holding current value
$1.45 Million
Previous $518,000
18.73%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding OLMA
# of Institutions
126Shares Held
68.8MCall Options Held
0Put Options Held
31.4K-
Bain Capital Life Sciences Investors, LLC Boston, MA6.84MShares$68.6 Million8.75% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY6.76MShares$67.8 Million1.35% of portfolio
-
Bvf Inc San Francisco, CA5.3MShares$53.1 Million0.89% of portfolio
-
Black Rock Inc. New York, NY4MShares$40.1 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA3.51MShares$35.1 Million0.08% of portfolio
About Olema Pharmaceuticals, Inc.
- Ticker OLMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,419,600
- Market Cap $405M
- Description
- Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...